Amorphical to Present Long-Term Phase 2 Crohn’s Data at ECCO 2026

Amorphical, a biotechnology company developing nano-amorphous mineral-based pharmacologic agents, has announced that long-term data from its Phase 2 trial in moderate-to-severe Crohn’s disease will be presented at the upcoming European Crohn's and Colitis Organisation Congress in Berlin.

The presentation builds on final results released in December 2025 and underscores the durability of the company’s investigational nano-amorphous calcium carbonate (ACC) therapy.

Durable Remission Without Immunosuppression

The 48-week follow-up data reveal that 62.5% of patients achieved sustained clinical remission, defined as a Crohn’s Disease Activity Index (CDAI) score below 150. Notably, the therapy demonstrated the ability to maintain remission well beyond the initial treatment period.

Unlike many current Crohn’s therapies, which rely on systemic immunosuppression, Amorphical’s ACC therapy is designed to offer a non-immunosuppressive pathway. This distinction could represent a meaningful shift in long-term disease management, particularly for patients concerned about the risks associated with immune-modulating drugs.

Dr. Arik Segal, lead investigator at Soroka University Medical Center, emphasized the significance of the findings. He highlighted the combination of rapid symptom relief and long-term durability—achieved without the systemic risks of immunosuppression—as a key differentiator. According to Dr. Segal, modulating the local inflammatory microenvironment through acid neutralization presents a viable, safe, and effective strategy for sustained disease control.

A Novel Mechanism of Action

Amorphical’s nano-amorphous ACC therapy works by targeting the inflammatory microenvironment in the gut. By optimizing local pH balance through acid neutralization, the therapy aims to reduce inflammation without suppressing the immune system broadly.

This mechanism may provide a new therapeutic category in Crohn’s disease treatment—one focused on disease modification through microenvironment regulation rather than immune suppression alone.

Dr. Segal will present the final 48-week data in a poster session titled “Sustained Clinical Remission in Moderate-to-Severe Crohn’s Disease via Nano-Amorphous ACC” on Friday, February 20, 2026.

Preparing for the Next Phase

The long-term results lay important groundwork for Amorphical’s upcoming regulatory submissions and its planned expansion of the Crohn’s clinical program into the United States. If further studies confirm these findings, the therapy could broaden the treatment landscape for patients seeking durable remission with fewer systemic risks.

About Amorphical

Amorphical is advancing a new class of nano-amorphous mineral pharmacologic agents based on a proprietary, nature-inspired platform. The company’s technology is designed to enhance bioavailability and optimize pH balance at the cellular level.

With nearly 200 patents, GMP-certified manufacturing infrastructure, and experience across multiple therapeutic areas—including pancreatic cancer, inflammatory diseases, and metabolic disorders—Amorphical is positioning itself at the forefront of scientifically validated, mineral-based disease-modifying therapies.

As interest grows in alternatives to traditional immunosuppressive treatments, Amorphical’s upcoming presentation at ECCO 2026 may mark an important milestone in the evolution of Crohn’s disease management.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!